1. Keene GS, Parker MJ, Pryor GA. Mortality and morbidity after hip fractures. BMJ.1993; 307: 1248-1250.
2. Drake MT, Murad MH, Mauck KF, Lane MA, Undavalli C, Elraiyah T, et al. Clinical review. Risk factors for low bone mass-related fractures in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2012; 97: 1861-1870.
3. Kanis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman JA, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int. 2005; 16: 155-162.
4. Yuan Z, Dawson N, Cooper GS, Einstadter D, Cebul R, Rimm AA. Effects of alcohol-related disease on hip fracture and mortality: a retrospective cohort study of hospitalized Medicare beneficiaries. Am J Public Health. 2001; 91: 1089-1093.
5. Qu X, Zhang X, Zhai Z, Li H, Liu X, Li H, et al. Association between physical activity and risk of fracture. J Bone Miner Res. 2014; 29: 202-211.
6. Te Riet L, van Esch JH, Roks AJ, van den Meiracker AH, Danser AH. Hypertension: renin-angiotensin-aldosterone system alterations. Circ Res. 2015; 116: 960-975.
7. Ilic K, Obradovic N, Vujasinovic-Stupar N. The relationship among hypertension, antihypertensive medications, and osteoporosis: a narrative review. Calcif Tissue Int. 2013; 92: 217-227.
8. Collaboration NCDRF. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet. 2017; 389: 37-55.
9. Abuohashish HM, Ahmed MM, Sabry D, Khattab MM, Al-Rejaie SS. ACE-2/Ang1-7/Mas cascade mediates ACE inhibitor, captopril, protective effects in estrogen-deficient osteoporotic rats. Biomed Pharmacother. 2017; 92: 58-68.
10. Chen S, Grover M, Sibai T, Black J, Rianon N, Rajagopal A, et al. Losartan increases bone mass and accelerates chondrocyte hypertrophy in developing skeleton. Mol Genet Metab. 2015; 115: 53-60.
11. Yang M, Xia C, Song Y, Zhao X, Wong MS, Zhang Y. Impairing effects of angiotensin-converting enzyme inhibitor Captopril on bone of normal mice. Eur J Pharmacol. 2016; 771: 40-47.
12. Kunutsor SK, Blom AW, Whitehouse MR, Kehoe PG, Laukkanen JA. Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and meta-analysis of published observational cohort studies. Eur J Epidemiol. 2017; 32: 947-959.
13. Carbone LD, Vasan S, Prentice RL, Harshfield G, Haring B, Cauley JA, et al. The renin-angiotensin aldosterone system and osteoporosis: findings from the Women's Health Initiative. Osteoporos Int. 2019; 30: 2039-2056.
14. Bokrantz T, Schioler L, Bostrom KB, Kahan T, Mellstrom D, Ljungman C, et al. Antihypertensive drug classes and the risk of hip fracture: results from the Swedish primary care cardiovascular database. J Hypertens. 2020; 38: 167-175.
15. Kao YT, Huang CY, Fang YA, Liu JC. The association between renin angiotensin aldosterone system blockers and future osteoporotic fractures in a hypertensive population - A population-based cohort study in Taiwan. Int J Cardiol. 2020; 305: 147-153.
16. McNutt LA, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol. 2003; 157: 940-943.
17. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998; 280: 1690-1691.
18. Danser AH, van den Meiracker AH. Response by Danser and van den Meiracker to Letter by Zhou and Zhou Regarding Article, "Hypertension: Renin-Angiotensin-Aldosterone System Alterations". Circ Res. 2016; 119: e105.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177-188.
20. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21: 1539-1558.
21. Solomon DH, Mogun H, Garneau K, Fischer MA. Risk of fractures in older adults using antihypertensive medications. J Bone Miner Res. 2011; 26: 1561-1567.
22. Choi HJ, Park C, Lee YK, Ha YC, Jang S, Shin CS. Risk of fractures in subjects with antihypertensive medications: A nationwide claim study. Int J Cardiol. 2015; 184: 62-67.
23. Ruths S, Bakken MS, Ranhoff AH, Hunskaar S, Engesaeter LB, Engeland A. Risk of hip fracture among older people using antihypertensive drugs: a nationwide cohort study. BMC Geriatr. 2015; 15: 153.
24. Torstensson M, Hansen AH, Leth-Moller K, Jorgensen TS, Sahlberg M, Andersson C, et al. Danish register-based study on the association between specific cardiovascular drugs and fragility fractures. BMJ Open. 2015; 5: e009522.
25. Chen HY, Ma KY, Hsieh PL, Liou YS, Jong GP. Long-term Effects of Antihypertensive Drug Use and New-onset Osteoporotic Fracture in Elderly Patients: A Population-based Longitudinal Cohort Study. Chin Med J (Engl). 2016; 129: 2907-2912.
26. Kwok T, Leung J, Barrett-Connor E, Osteoporotic Fractures in Men Research G. ARB users exhibit a lower fracture incidence than ACE inhibitor users among older hypertensive men. Age Ageing. 2017; 46: 57-64.
27. Asaba Y, Ito M, Fumoto T, Watanabe K, Fukuhara R, Takeshita S, et al. Activation of renin-angiotensin system induces osteoporosis independently of hypertension. J Bone Miner Res. 2009; 24: 241-250.
28. Shuai B, Yang YP, Shen L, Zhu R, Xu XJ, Ma C, et al. Local renin-angiotensin system is associated with bone mineral density of glucocorticoid-induced osteoporosis patients. Osteoporos Int. 2015; 26: 1063-1071.
29. Hagiwara H, Hiruma Y, Inoue A, Yamaguchi A, Hirose S. Deceleration by angiotensin II of the differentiation and bone formation of rat calvarial osteoblastic cells. J Endocrinol. 1998; 156: 543-550.
30. Izu Y, Mizoguchi F, Kawamata A, Hayata T, Nakamoto T, Nakashima K, et al. Angiotensin II type 2 receptor blockade increases bone mass. J Biol Chem. 2009; 284: 4857-4864.
31. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002; 110: 229-238.
32. Tomaschitz A, Pilz S, Ritz E, Grammer T, Drechsler C, Boehm BO, et al. Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin Chim Acta. 2010; 411: 1354-1360.
33. Forman JP, Williams JS, Fisher ND. Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. Hypertension. 2010; 55: 1283-1288.
34. Agarwal D, Welsch MA, Keller JN, Francis J. Chronic exercise modulates RAS components and improves balance between pro- and anti-inflammatory cytokines in the brain of SHR. Basic Res Cardiol. 2011; 106: 1069-1085.
35. Barretti DL, Magalhaes Fde C, Fernandes T, do Carmo EC, Rosa KT, Irigoyen MC, et al. Effects of aerobic exercise training on cardiac renin-angiotensin system in an obese Zucker rat strain. PLoS One. 2012; 7: e46114.
36. Ciampone S, Borges R, de Lima IP, Mesquita FF, Cambiucci EC, Gontijo JA. Long-term exercise attenuates blood pressure responsiveness and modulates kidney angiotensin II signalling and urinary sodium excretion in SHR. J Renin Angiotensin Aldosterone Syst. 2011; 12: 394-403.
37. Aubert J, Darimont C, Safonova I, Ailhaud G, Negrel R. Regulation by glucocorticoids of angiotensinogen gene expression and secretion in adipose cells. Biochem J. 1997; 328 ( Pt 2): 701-706.
38. Ferrario CM, VonCannon J, Jiao Y, Ahmad S, Bader M, Dell'Italia LJ, et al. Cardiac angiotensin-(1-12) expression and systemic hypertension in rats expressing the human angiotensinogen gene. Am J Physiol Heart Circ Physiol. 2016; 310: H995-1002.
39. Roig E, Perez-Villa F, Morales M, Jimenez W, Orus J, Heras M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J. 2000; 21: 53-57.
40. Park S, Bivona BJ, Kobori H, Seth DM, Chappell MC, Lazartigues E, et al. Major role for ACE-independent intrarenal ANG II formation in type II diabetes. Am J Physiol Renal Physiol. 2010; 298: F37-48.
41. Dusing R. Mega clinical trials which have shaped the RAS intervention clinical practice. Ther Adv Cardiovasc Dis. 2016; 10: 133-150.
42. El Muayed M, Stegbauer J, Oberhauser V, Vonend O, Rump LC. AT1 and AT2-receptor antagonists inhibit Ang II-mediated facilitation of noradrenaline release in human atria. J Cardiovasc Pharmacol. 2004; 43: 318-324.
43. Siragy HM. AT1 and AT2 receptor in the kidney: role in health and disease. Semin Nephrol. 2004; 24: 93-100.
44. Steckelings UM, Kaschina E, Unger T. The AT2 receptor--a matter of love and hate. Peptides. 2005; 26: 1401-1409.
45. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000; 52: 415-472.
46. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992; 117: 234-242.
47. Kostis WJ, Shetty M, Chowdhury YS, Kostis JB. ACE Inhibitor-Induced Angioedema: a Review. Curr Hypertens Rep. 2018; 20: 55.
48. Srivastava S, Sharma K, Kumar N, Roy P. Bradykinin regulates osteoblast differentiation by Akt/ERK/NFkappaB signaling axis. J Cell Physiol. 2014; 229: 2088-2105.
49. Khosla S. Update on estrogens and the skeleton. J Clin Endocrinol Metab. 2010; 95: 3569-3577.